INSIGHTS ON PHARMACEUTICAL LOGISTICS

• Friendshoring: A Strategic Shift In Pharma Supply Chains

  To safeguard the consistent delivery of essential therapies to patients around the world, biopharmaceutical companies, alongside their CDMO partners, are rethinking traditional supply models.

• Biopharma Supply, Reimagined: Blarney, A Climate-Neutral Facility For Best-In-Class Filters

  Explore how a new, climate-neutral manufacturing facility strengthens biopharma supply chains. Understand the benefits of its advanced filtration technologies and commitment to environmental sustainability.

• Integrated Single-Site CDMO Model

  A single‑site model reduces handoff risks, speeds timelines, strengthens quality oversight, and unifies development and manufacturing to improve reliability and execution efficiency.

• Global Complexity Demands Local Resilience

  With integrated capabilities spanning early development through commercial manufacturing, our U.S. network helps customers build greater supply chain resilience, navigate uncertainty, and create a more reliable path to market.

• The Crucial Role Of Cleaning In Effective VPHP Decontamination For Isolators

  12/27/2024

  Effective isolator cleaning is crucial for vapor phase hydrogen peroxide (VPHP) decontamination. Proper tools, techniques, and training ensure sterility, and regulatory compliance.

• Food Safety Digital Maturity In The Supply Chain

  3/17/2026

  Look at how connected data and automated processes strengthen safety, improve traceability, and streamline compliance across the supply chain—offering a clear roadmap for progression.

• Top Safety Considerations In Biopharmaceutical Manufacturing

  4/16/2025

  Understanding top safety concerns, from combustible material handling and chemical exposure to HPAPIs, is the first step toward preventing accidents in biopharmaceutical manufacturing environments.

• How To Select The Right Fill-Finish CDMO For Phase I–II

  3/16/2026

  Early‑phase programs require flexible, technically aligned fill‑finish partners. Mid‑sized CDMOs offer a balance of agility, infrastructure, and regulatory maturity suited to Phase I–II needs.

• Strengthen Pharmaceutical Supply Chains With A U.S.-Based CDMO

  6/5/2025

  While certain ingredients require sourcing abroad, partnering with a U.S.-based company that owns its manufacturing assets allows for direct oversight of product quality and supply reliability.